Individualizing Neo/Adjuvant Treatment in Early Breast Cancer Care: Education, Tools, and Resources for Patients and Providers

In this commentary, I share my thoughts on the impact of recent data on treatment planning in early breast cancer, including how to incorporate PARP inhibition, CDK4/6 inhibition, and immunotherapy, along with the dilemmas and challenges surrounding their use.

Denise A. Yardley, MD Released: February 22, 2022

This module offers an overview of current risk assessment and biomarker testing used to inform treatment decisions and predict treatment response and prognosis in patients with HER2-negative early breast cancer.

Yara Abdou, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 6, 2022 Expired: April 5, 2023

This module offers an expert analysis of the role of Ki-67 in risk assessment and discusses recently approved adjuvant abemaciclib for patients with HR-positive, HER2-negative EBC at high risk of recurrence.

Yara Abdou, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 12, 2022 Expired: May 11, 2023

In this module, an expert reviews germline BRCA mutations, biomarker testing, and adjuvant olaparib in the management of patients with gBRCA1/2-mutated, HER2-negative, high-risk early breast cancer.

Yara Abdou, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: May 17, 2022 Expired: May 16, 2023

This slideset offers an overview of current risk assessment and biomarker testing used to inform treatment decisions and predict treatment response and prognosis in patients with HER2-negative early breast cancer.

Yara Abdou, MD Released: April 6, 2022

This slideset accompanies an expert analysis of the role of Ki-67 in risk assessment and discusses recently approved adjuvant abemaciclib for patients with HR-positive, HER2-negative EBC at high risk of recurrence.

Yara Abdou, MD Released: May 12, 2022

Downloadable slideset describing germline BRCA mutations, biomarker testing, and adjuvant olaparib in the management of patients with gBRCA1/2-mutated, HER2-negative, high-risk early breast cancer.

Yara Abdou, MD Released: May 17, 2022